Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-8998 in IGE with Absence Seizures
NCT03406702Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Feb 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of suvecaltamide in idiopathic generalized epilepsy (IGE), sponsored by Jazz Pharmaceuticals plc. Started Feb 2018; status: completed.
02
Drugs
suvecaltamide
03
Conditions
idiopathic generalized epilepsy (IGE)
Beyond the preview
Go deeper on NCT03406702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406702.